MedElevator Войти в исследования
← Поиск публикаций

DOI 10.7399/fh.2016.40.3.8905

Медицинская библиотека · Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria · 2016

Study on adherence to treatment with imatinib in chronic myeloid leukaemia and its association with therapeutic response.

García-Queiruga Marta, Martínez-López Laura María, Martín-Herranz María Isabel, Seoane-Pillado Teresa, Fernández-Gabriel Elena, Calleja-Chuclá Teresa

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVE

To assess the level of adherence to treatment with imatinib in patients with chronic myeloid leukaemia and its association with therapeutic response.

MATERIALS AND

METHODS

Study conducted on October, 2013 - March, 2014, including patients diagnosed with Chronic Myeloid Leukaemia on treatment with imatinib in the hospital. Therapeutic adherence was assessed through the standard Morisky-Green Questionnaire and the medication dispensing record. Those patients who did not complete 6 months of treatment and/or did not complete the questionnaire were excluded. Therapeutic response was assessed following clinical guidelines. The descriptive analysis of variables and correlation was conducted through Pearsons's Chi-Square Test.

RESULTS

The study included 31 patients. When assessing the level of association between response variables and therapeutic adherence: 1. The highest molecular response was reached by 68.4% of those patients with high adherence, and by 75% of those patients with intermediate adherence. 2. Complete molecular response was achieved by 57.9% of patients with high adherence, and by 58.3% of patients with intermediate adherence. No statistically significant differences were found in response variables between patients with high and intermediate therapeutic adherence. No association was observed between level of adherence and therapeutic response.

CONCLUSIONS

We cannot confirm that a different level of therapeutic adherence might have an impact on response to imatinib, though this should be taken into account in cases of therapeutic failure or sub-optimal response.

Для цитирования: García-Queiruga Marta, Martínez-López Laura María, Martín-Herranz María Isabel, Seoane-Pillado Teresa, Fernández-Gabriel Elena, Calleja-Chuclá Teresa. Study on adherence to treatment with imatinib in chronic myeloid leukaemia and its association with therapeutic response.. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 2016. DOI: 10.7399/fh.2016.40.3.8905.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.